Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR

Classificação em ações #36459
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Preço da ação
$1.73
Última sincronização: 2025-06-17
Valor de mercado
$2.55M
Variação (1 dia)
-0.29%
Variação (1 ano)
-79.71%
País
US
Negociar Eiger BioPharmaceuticals, Inc. (EIGR)

Categoria

Healthcare
Rácio P/S de Eiger BioPharmaceuticals, Inc. (EIGR)
Rácio P/S em October 2026 TTM: 0.80
De acordo com os relatórios financeiros mais recentes e o preço das ações da Eiger BioPharmaceuticals, Inc., o rácio P/S atual (TTM) é 0.80. No final de 2022, o rácio P/S era 3.64.
Histórico do rácio P/S da Eiger BioPharmaceuticals, Inc. de 2016 a 2026
Rácio P/S no final de cada ano
Ano Rácio P/S Alterar
2026 (TTM) 0.80 20.91%
2023 0.66 -81.89%
2022 3.64 -74.89%
2021 14.51 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
Rácio P/S de empresas semelhantes ou concorrentes
Empresa Rácio P/S Diferença do rácio P/S País
10.02 1,155.90%
US
40.55 4,981.55%
US
3.96 396.38%
AU
- -
CH
10.15 1,171.47%
NL